ED
NBRV

Exane Derivatives’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Exane Derivatives’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-540
Closed -$71.9K – 881
2020
Q3 		$71.9K Buy
540
+100
+23% +$16.7K 0.02% 347
2020
Q2 		$74.3K Buy
440
+112
+34% +$18.7K 0.02% 324
2020
Q1 		$47.2K Buy
+328
New +$100K 0.01% 355

Other funds holding NBRV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
AICPI
ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

Exane Derivatives's NBRV Position: Q4 2020 in Review

Exane Derivatives sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q4 2020, closing a stake of 540 shares — an estimated $71.9K sold.

Exane Derivatives first reported a position in NBRV in Q1 2020 and held it in 3 quarters. The position peaked at $74.3K in Q2 2020. 33 funds tracked by Wall St. Rank hold NBRV as of Q4 2020.

  • Exane Derivatives reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q4 2020 after selling out during the quarter.
  • Exane Derivatives sold 540 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q4 2020, an estimated $71.9K.
  • Exane Derivatives first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q1 2020 and held it in 3 quarters.
  • Exane Derivatives's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $74.3K in Q2 2020.
  • 33 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q4 2020.

Based on Exane Derivatives's 13F filing for Q4 2020, filed 27 Jan 2021.